Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

33.54
-1.1950-3.44%
Post-market: 33.51-0.0249-0.07%19:55 EDT
Volume:4.04M
Turnover:135.40M
Market Cap:3.77B
PE:-21.82
High:34.89
Open:32.90
Low:32.76
Close:34.73
52wk High:81.73
52wk Low:18.92
Shares:112.44M
Float Shares:109.98M
Volume Ratio:0.87
T/O Rate:3.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5368
EPS(LYR):-1.0085
ROE:-19.99%
ROA:-14.99%
PB:4.74
PE(LYR):-33.25

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE- SLB NV, Bank OZK, Gilead Sciences

Reuters
·
Yesterday

Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?

Motley Fool
·
Oct 16

Viking Therapeutics Inc. to Release Third Quarter 2025 Financial Results

Reuters
·
Oct 16

Will Progress in VK2735 Weight Loss Trials Change Viking Therapeutics' (VKTX) Narrative?

Simply Wall St.
·
Oct 15

Down 44%, Should You Buy the Dip on Viking Therapeutics?

Motley Fool
·
Oct 13

Why Shares in Viking Therapeutics Surged This Week

Motley Fool
·
Oct 10

Viking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline

Reuters
·
Oct 02

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 29

Viking Therapeutics: Promising Position in GLP-1 Market with Strategic Growth Potential

TIPRANKS
·
Sep 29

US STOCKS-Wall Street futures mixed as investors brace for inflation data

Reuters
·
Sep 26

Shares of Some US Drugmakers Rise Premarket After Trump Announces New Pharma Tariffs

THOMSON REUTERS
·
Sep 26

Eli Lilly up 1.7%, Viking Therapeutics Adds 1.4%

THOMSON REUTERS
·
Sep 26

Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.

Motley Fool
·
Sep 25

Viking Therapeutics Highlights Advancements in Obesity and Metabolic Disease Pipeline in New Corporate Presentation

Reuters
·
Sep 25

Viking Therapeutics: Strong Buy Rating Amid Strategic Positioning and Acquisition Potential in the Metabolic Disease Market

TIPRANKS
·
Sep 22

Viking Therapeutics Price Target Maintained With a $125.00/Share by BTIG

Dow Jones
·
Sep 22

Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months

Motley Fool
·
Sep 19

Viking Therapeutics Shares Down 3.8% After Rival Eli Lilly's Glp-1 Pill Helps Cut Body Weight in Late Stage Study of Diabetes Patients

THOMSON REUTERS
·
Aug 26

Goldman Sachs Reviews Viking Therapeutics (VKTX.US) Oral Drug VK2735 Trial Results: Significant Efficacy but Questionable Tolerability, Better Suited for Weight Maintenance

Stock News
·
Aug 21

Stock Track | Viking Therapeutics Soars 5.05% Despite Mixed Results from Obesity Drug Trial

Stock Track
·
Aug 20